Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Immuneering (Nasdaq: IMRX) said CEO Ben Zeskind will speak in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026 at 3:45 p.m. ET. The session will be webcast live and archived in the company's Investor Relations Events & Presentations section.
Positive
- None.
Negative
- None.
News Market Reaction – IMRX
In the Apr 7 session, IMRX declined 3.15%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 17 | AACR data preview | Positive | -0.4% | Planned AACR molecular data on atebimetinib-treated RAS-mutant solid tumor patients. |
| Mar 6 | Earnings and updates | Positive | +7.0% | Q4/FY 2025 results, 64% 12‑month OS, strong cash and Phase 3 timeline. |
| Mar 2 | Conference appearance | Neutral | -1.0% | Leerink Global Healthcare Conference fireside chat and 1x1 investor meetings. |
| Feb 18 | Conference appearance | Neutral | +4.4% | Oppenheimer virtual conference company presentation and investor meetings. |
| Jan 7 | Clinical data update | Positive | -43.2% | Updated Phase 2a pancreatic cancer data with 64% 12‑month OS and strong efficacy. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows mixed alignment: positive clinical/earnings updates have sometimes sold off sharply, while routine conference appearances have generally seen modest, aligned reactions.
Over the last six months, Immuneering has reported multiple clinical and corporate milestones. On Jan 7, strong Phase 2a pancreatic data coincided with a -43.22% move, contrasting with a +7.03% reaction to upbeat 2025 earnings and cash runway on Mar 6. Subsequent AACR molecular data on Mar 17 saw a mild decline. Several recent appearances at investor and healthcare conferences (Feb–Mar 2026) have produced relatively modest stock moves, similar in nature to today’s Needham conference participation announcement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that Ben Zeskind, Chief Executive Officer, will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 3:45 p.m. ET. The fireside chat will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.
About Immuneering
Immuneering is a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors, designed to improve overall survival by three mechanisms: shrinking tumors durably with less resistance, preserving body mass by countering cachexia, and minimizing side effects to maximize performance status and combinability. Immuneering’s lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve survival across many cancer indications, including MAPK pathway-driven tumors such as pancreatic cancer. The company expects to dose the first patient in mid-2026 in MAPKeeper 301, a globally randomized pivotal Phase 3 trial evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company’s development pipeline also includes additional combination opportunities and early-stage programs. For more information, please visit www.immuneering.com.
Investor Contact:
Courtney Dugan
Cdugan@immuneering.com
Media Contact:
Gina Nugent
Gina.nugent.external@immuneering.com
